Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

The projected decline in NATCOPHARM's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.

Financial Ratios:

currentRatio 0.000000
forwardPE 8.077124
debtToEquity 2.912000
earningsGrowth -0.375000
revenueGrowth -0.374000
grossMargins 0.856240
operatingMargins -0.017270
trailingEps 104.160000
forwardEps 41.270000

NATCO Pharma Limited's low earnings and revenue growth suggest shrinking profits. This negative trend could indicate that the company is struggling to maintain its financial performance and may face challenges ahead.
NATCO Pharma Limited's negative gross and operating margins indicate the company is operating at a loss, unable to generate profit from its core business activities. This suggests financial strain and potential challenges in maintaining profitability.
NATCO Pharma Limited's forward EPS being less than its trailing EPS indicates the company may be less profitable this year than last. This signals potential challenges in maintaining earnings growth and could lead to concerns about future performance.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


There were 20 NATCO Pharma Limited stock sales, with market price at 1344.6024963378907.1 transactions to buy NATCOPHARM occurred, with market price at 821.5999755859375.With more buys than sells around NATCOPHARM's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


With analysts showing a buy bias for NATCOPHARM, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning NATCOPHARM as a safe and profitable place for investors to allocate their funds and seek growth.